ProSomnus To Design Head-to-Head Clinical Trial vs. Hypoglossal Nerve Stimulation
Portfolio Pulse from Benzinga Newsdesk
ProSomnus, Inc. (NASDAQ:OSA), a leading CPAP alternative for the treatment of Obstructive Sleep Apnea (OSA), has announced plans to design a head-to-head clinical trial comparing its precision oral appliance therapy (OAT) and hypoglossal nerve stimulation (HNS) in treating patients with severe OSA.
July 13, 2023 | 12:01 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
ProSomnus' announcement of a head-to-head clinical trial for its OAT and HNS treatments could potentially boost investor confidence in the company's commitment to innovation and patient care.
The announcement of a new clinical trial indicates that ProSomnus is actively working on improving its products and services. This could potentially attract more investors and increase the company's stock price in the short term.
CONFIDENCE 80
IMPORTANCE 75
RELEVANCE 100